Clinical standard-risk and intermediate-risk patients with MRD of 001 % or higher at day 29 of induction ( MRD high risk ) were randomly assigned ( 1:1 ) to standard therapy ( treatment regimens A and B ) or augmented post-remission therapy ( regimen C ) .